GlassScriptPhysician profile
Heather C Buckner
NPI 1972045797
$2,242.41
in general payments reported to CMS, 2019-2025
23 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $343 · 2024: $1,484 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.42 | 2021-2025 | Wegovy |
| Amgen INC. | $462.39 | 2024 | Enbrel, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $176.20 | 2022-2024 | Saphnelo |
| Janssen Biotech, INC. | $127.29 | 2024 | Tremfya |
| Lilly USA, LLC | $125.88 | 2024-2025 | Zepbound, Taltz |
| Pfizer INC. | $124.61 | 2024 | |
| Abbvie INC. | $104.60 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $90.73 | 2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $69.12 | 2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $66.95 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $66.78 | 2024 | Uptravi, Opsumit |
| Organon LLC | $54.77 | 2024 | |
| Mallinckrodt Hospital Products INC. | $46.80 | 2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.33 | 2024 | Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $40.40 | 2024 | Idacio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $31.51 | 2024 | Quzyttir |
| Glaxosmithkline, LLC. | $24.50 | 2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $24.29 | 2022 | |
| Ucb, INC. | $22.06 | 2024 | Cimzia |
| Kiniksa Pharmaceuticals International, Plc | $21.68 | 2024 | Arcalyst |
| Sandoz INC. | $21.46 | 2024 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $20.76 | 2024 | Lupkynis |
| Currax Pharmaceuticals LLC | $14.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.